Business Wire

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Share

Boehringer Ingelheim and Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL), have announced that Boehringer Ingelheim plans to initiate Phase 2 development of the GLP-1/glucagon dual agonist BI 456906, which was in-licensed from Zealand. Boehringer Ingelheim and Zealand have a longstanding partnership, bringing together Zealand’s expertise in the discovery of innovative peptide-based medicines with Boehringer Ingelheim’s expertise in the research and development of novel medicines for cardiometabolic diseases.

The compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has potential as a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.1 It is part of Boehringer Ingelheim’s growing research and development stage portfolio in the obesity and diabetes disease areas.

The decision to advance BI 456906 to Phase 2 clinical testing is based on the safety and tolerability and the favorable weight loss potential in individuals with a BMI up to 40 kg/m2. The Phase 2 trial will be a dose-finding, placebo and active comparator clinical proof of concept trial in patients with obesity and type 2 diabetes.

“We believe that BI 456906 has great therapeutic potential, and we are thrilled to see it advance into Phase 2 development,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Our strong partnership with Boehringer Ingelheim unites expertise and capabilities to achieve a shared vision of helping millions of people better manage and overcome obesity and type 2 diabetes.”

“We are excited to see this candidate from our dedicated and productive long-term collaboration with Zealand Pharma proceed to the next stage of clinical studies,” explained Clive R. Wood, Ph.D., Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “This brings us an important step further to bringing BI 456906 to the many patients that are in need of new treatment options.”

Zealand has licensed two product candidates to Boehringer Ingelheim, both with potential for once-weekly administration. Under the terms of the two agreements, Boehringer Ingelheim funds all research, development and commercialization activities. For the GLP1/glucagon dual agonist, Zealand is entitled to receive up to EUR 365 million in outstanding milestone payments and will receive a milestone payment of EUR 20 million related to initiation of Phase 2. The agreement also carries high-single digit to low-double digit percentage royalties on global sales. The other collaboration compound is a long-acting amylin analog for which Zealand is entitled to receive up to EUR 283 million in outstanding milestone payments, and mid-single digit to low-double digit percentage royalties on global sales.

Excessive weight and obesity are amongst the leading risk factors for heart disease, ischemic stroke, liver diseases and type 2 diabetes as well as for a number of cancers. There are insufficient therapeutic options available, resulting in a high unmet medical need for safe and effective treatments that achieve significant weight loss. Boehringer Ingelheim’s track record of excellence in research and development in cardiometabolic diseases is evidence of its innovation which has resulted in important breakthroughs in recent years, especially in thromboembolic diseases and type 2 diabetes.

Please click on the following link for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/collaboration-zealand-pharma-advances-phase-ii

Contact information

Media Contacts:
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
press@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Zealand Pharma A/S
Emmanuel Dulac
President and Chief Executive Officer
Tel.: +45 50 60 36 36

Lani Pollworth Morvan
Investor Relations and Communication
Tel.: +45 50 60 37 78
lpm@zealandpharma.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ISACA Combines EuroCACS and CSX Conferences for the First Time in ISACA’s 50th Anniversary Year17.9.2019 14:15:00 CESTPress release

Digital transformation and emerging technologies are the focus of ISACA’s combined EuroCACS/Cybersecurity Nexus (CSX) conference in Geneva, Switzerland, from 16-18 October 2019, as ISACA continues celebrating its 50th anniversary year. Sessions focused on DevOps, Agile, cryptocurrency, mobile payments, the Internet of Things (IoT), and other hot topics will bring together business technology professionals who lead information systems audit, risk, governance and security functions at their enterprises. Keynote speaker Anders Sorman-Nillson, a global futurist and innovation strategist, will open EuroCACS/CSX, and entrepreneur Jon Duschinsky, who was voted the second-most influential communicator in social innovation, will deliver the closing keynote. Also planned is a general-session panel to mark ISACA’s 50th anniversary in 2019 that features industry experts in innovation and a concurrent general session on “The Weaponisation of the IoT.” Attendees can advance their skills across techn

Andersen Global Expands in Rwanda17.9.2019 13:30:00 CESTPress release

Andersen Global announced today a collaboration agreement with MRB Attorneys in Rwanda. The addition of the Kigali-based firm marks the 16th country with a presence in Africa for Andersen Global. MRB Attorneys was founded in 2013 by the firm’s five partners, who all have extensive experience in private and public legal consultancy services. Today, MRB’s eleven attorneys advise clients in corporate and commercial law, dispute resolution, energy and infrastructure, and government business and policy, with a heavy emphasis on banking and investment issues. They represent a broad clientele of banks, private and public companies, international organizations, and government agencies. “Andersen Global’s reputation of stewardship and transparency lines up well with what our clients value and have come to expect from us. The synergetic collaboration will be beneficial for our clients and our people,” said Emmanuel Butare, MRB Attorneys’ Managing Partner. “We are excited to work with like-minded

Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment17.9.2019 13:15:00 CESTPress release

There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devices suppliers. Cancer treatment is one of medical specialties that Taiwan gains recognition in Asia. The focal point now goes to proton therapy, which is proven to be a painless way to deliver radiation dose in targeted tumours precisely and maintains side effects happening in the minimum level. Proton therapy key players race for Asia markets Despite proton therapy indicating a promising alternative for cancer treatments, it is far from close to a mainstream service that can be found in medical institutes. As per PTCOG statistics, there are 82 medical institutes to date having the therapy on offer, with one in operation and 9 to go in Taiwan- the highest density as opposed to the rest of the world. Chang Gung Memorial Hospital launched the service in 2015, followed closely by its peers inc

CE China 2019: The International Brand Show for Consumer and Home Electronics17.9.2019 13:13:00 CESTPress release

For the first time, CE China - a global IFA event - is held from 19 to 21 September 2019 in Guangzhou, the heart of China's trade and manufacturing business. The new date in September is perfect for preparation of Singles Day and end of year business in Asia. CE China provides an ideal platform and comprehensive services for consumer electronics and home appliance brands. The show has successfully established partnerships with leading global retailer chains such as Suning and Alibaba’s Tmall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005728/en/ Autonomous driving and new mobility at CE China 2019 CE China 2019 includes Connected Driving and New Energy Vehicles section in its spectrum tackling the trend of autonomous driving. Today, intelligent interconnection is not only a major trend in household appliances and electronic consumer goods, but also key to the automotive industry – bringing consumer electronics, hou

Zscaler Extends Edge Compute, Now Operating in Over 150 Data Centers17.9.2019 13:00:00 CESTPress release

Zscaler, Inc., the leader in cloud security, today announced the Zscaler™ platform is now distributed across over 150 data centers, with the company’s latest data center opening in Val-du-Roi, Normandy, France. The expansion is part of the company’s ongoing mission to provide enterprise users with fast, secure, reliable access to applications and services regardless of location, empowering enterprises to accelerate their cloud adoption, securely. Built on the Zscaler multi-tenant cloud architecture, the Zscaler platform unifies secure internet gateway services, cloud sandbox, next-generation cloud firewall, data loss prevention, SSL decryption, bandwidth control, and more, with simplified policy management and reporting. It is now distributed across more than 150 data centers on six continents, which enables users to access the internet and cloud services securely from any device, any location, and over any network. “The physical footprint and end-to-end control of the network, infrast

Quake Global Launches Global LTE as the Latest Innovation for Our Best-Selling Products, QPRO™ and Q4000™17.9.2019 13:00:00 CESTPress release

Quake Global, Inc. is excited to announce the availability of global LTE in our best-selling products, QPRO™ and Q4000™, which both come with bi-directional and dual-mode communication protocols over global satellite and cellular networks. Q4000 and QPRO are now available to our customers across the globe featuring the latest LTE communication technology, Cat M1/NB-IoT. This technology is designed to support M2M markets with a special focus on lower data costs for IoT data-driven applications. LTE is ideal for our customers who have equipment spanning significant geographic areas. The robust hardware housing and platform are designed to withstand extreme weather conditions, challenging work environments and are built to last. “At Quake, we continually strive to bring the most advanced telecommunication technology to our customers to ensure connectivity to assets in every part of the world,” said Polina Braunstein, CEO and President of Quake Global. Quake’s QRO and Q4000 family of produ